JOSE ANTONIO SANCHES JUNIOR

(Fonte: Lattes)
Índice h a partir de 2011
22
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Dermatologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Colaboração internacional: Alemanha ×

Resultados de Busca

Agora exibindo 1 - 10 de 23
  • conferenceObject
    Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas: an EORTC CLTF study
    (2022) MITSUNAGA, K.; BAGOT, M.; BEYLOT-BARRY, M.; RAM-WOLFF, C.; GUENOVA, E.; FASSNACHT, C.; HODAK, E.; AMITAY, I.; PAPADAVID, E.; JONAK, C.; PORKERT, S.; SCARISBRICK, J.; APPLEWAITE, R.; NICOLAY, J.; QUAGLINO, P.; SANCHES JR., J.; MARTINS, J. Cury; ORTIZ-ROMERO, P. L.
  • conferenceObject
    ISCL/USCLC/EORTC guidelines for the diagnosis, staging, and treatment of pediatric mycosis fungoides
    (2023) HODAK, Emilia; AMITAY-LAISH, Iris; BAGOT, Martine; BATTISTELLA, Maxime; COZZIO, Antonio; DUVIC, Madeleine; GESKIN, Larisa; GUENOVA, Emmanuela; KIM, Youn H.; NICOLAY, Jan; ORTIZ-ROMERO, Pablo Luis; OSMANCEVIC, Amra; PAPADAVID, Evangelia; QUAGLINO, Pietro; SANCHES, Jose A.; SCARISBRICK, Julia; STADLER, Rudolf; TRAUTINGER, Franz; VERMEER, Maarten; ASSAF, Chalid
  • article 65 Citação(ões) na Scopus
    Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study
    (2020) MOLLOY, K.; JONAK, C.; WOEI-A-JIN, F. J. S. H.; GUENOVA, E.; BUSSCHOTS, A. M.; BERVOETS, A.; HAUBEN, E.; KNOBLER, R.; PORKERT, S.; FASSNACHT, C.; COWAN, R.; PAPADAVID, E.; BEYLOT-BARRY, M.; BERTI, E.; VIOLETTI, S. Alberti; ESTRACH, T.; MATIN, R.; AKILOV, O.; VAKEVA, L.; PRINCE, M.; BATES, A.; BAYNE, M.; WACHSMUCH, R.; WEHKAMP, U.; MARSCHALKO, M.; SERVITJE, O.; TURNER, D.; WEATHERHEAD, S.; WOBSER, M.; SANCHES, J. A.; MCKAY, P.; KLEMKE, D.; PENG, C.; HOWLES, A.; YOO, J.; EVISON, F.; SCARISBRICK, J.
    Background Mycosis fungoides (MF) and Sezary Syndrome (SS) are the most common cutaneous T-cell lymphomas. MF/SS is accompanied by considerable morbidity from pain, itching and disfigurement. Aim To identify factors associated with poorer health-related quality of life (HRQoL) in patients newly diagnosed with MF/SS. Methods Patients enrolled into Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI; an international observational study in MF/SS) had their HRQoL assessed using the Skindex-29 questionnaire. Skindex-29 scores were analysed in relation to patient- and disease-specific characteristics. Results The study population consisted of 237 patients [60 center dot 3% male; median age 60 years, (interquartile range 49-70)], of whom 179 had early MF and 58 had advanced MF/SS. In univariate analysis, HRQoL, as measured by Skindex-29, was worse in women, SS, late-stage MF, those with elevated lactate dehydrogenase, alopecia, high modified Severity Weighted Assessment Tool and confluent erythema. Linear regression models only identified female gender (beta = 8 center dot 61; P = 0 center dot 003) and alopecia (beta = 9 center dot 71, P = 0 center dot 02) as independent predictors of worse global HRQoL. Item-level analysis showed that the severe impairment in symptoms [odds ratio (OR) 2 center dot 14, 95% confidence interval (CI) 1 center dot 19-3 center dot 89] and emotions (OR 1 center dot 88, 95% CI 1 center dot 09-3 center dot 27) subscale scores seen in women was caused by more burning/stinging, pruritus, irritation and greater feelings of depression, shame, embarrassment and annoyance with their diagnosis of MF/SS. Conclusions HRQoL is significantly more impaired in newly diagnosed women with MF/SS and in those with alopecia. As Skindex-29 does not include existential questions on cancer, which may cause additional worry and distress, a comprehensive validated cutaneous T-cell lymphoma-specific questionnaire is urgently needed to more accurately assess disease-specific HRQoL in these patients.
  • conferenceObject
    An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study
    (2019) MOLLOY, K.; JONAK, C.; SHERIDA, F. J.; WOEI-A-JI, H.; GUENOVA, E.; BUSSCHOTS, A. M.; BERVOETS, A.; HAUBEN, E.; KNOBLER, R.; PORKERT, S.; FASSNACHT, C.; COWAN, R.; PAPADAVID, E.; BEYLOT-BARRY, M.; BERTI, E.; VIOLETTI, S. Alberti; ESTRACH, T.; MATIN, R.; AKILOV, O.; VAKEVA, L.; PRINCE, M.; BATES, A.; BAYNE, M.; WACHSMUCH, R.; WEHKAMP, U.; MARSCHALKO, M.; SERVITJE, O.; TURNER, D.; WEATHERHEAD, S.; WOBSER, M.; SANCHES, J. Antonio; MCKAY, P.; KLEMKE, D.; HOWLES, A.; YOO, J.; EVISON, F.; SCARISBRICK, J.
  • article 438 Citação(ões) na Scopus
    Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
    (2017) PRINCE, H. Miles; KIM, Youn H.; HORWITZ, Steven M.; DUMMER, Reinhard; SCARISBRICK, Julia; QUAGLINO, Pietro; ZINZANI, Pier Luigi; WOLTER, Pascal; SANCHES, Jose A.; ORTIZ-ROMERO, Pablo L.; AKILOV, Oleg E.; GESKIN, Larisa; TROTMAN, Judith; TAYLOR, Kerry; DALLE, Stephane; WEICHENTHAL, Michael; WALEWSKI, Jan; FISHER, David; DRENO, Brigitte; STADLER, Rudolf; FELDMAN, Tatyana; KUZEL, Timothy M.; WANG, Yinghui; PALANCA-WESSELS, Maria Corinna; ZAGADAILOV, Erin; TREPICCHIO, William L.; ZHANG, Wenwen; LIN, Hui-Min; LIU, Yi; HUEBNER, Dirk; LITTLE, Meredith; WHITTAKER, Sean; DUVIC, Madeleine
    Background Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. Methods In this international, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously treated. Patients were enrolled across 52 centres in 13 countries. Patients were randomly assigned (1:1) centrally by an interactive voice and web response system to receive intravenous brentuximab vedotin 1.8 mg/kg once every 3 weeks, for up to 16 3-week cycles, or physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m(2) once per day) for up to 48 weeks. The primary endpoint was the proportion of patients in the intention-totreat population achieving an objective global response lasting at least 4 months per independent review facility. Safety analyses were done in all patients who received at least one dose of study drug. This trial was registered with ClinicalTrials.gov, number NCT01578499. Findings Between Aug 13, 2012, and July 31, 2015, 131 patients were enrolled and randomly assigned to a group (66 to brentuximab vedotin and 65 to physician's choice), with 128 analysed in the intention-to-treat population (64 in each group). At a median follow-up of 22.9 months (95% CI 18.4-26.1), the proportion of patients achieving an objective global response lasting at least 4 months was 56.3% (36 of 64 patients) with brentuximab vedotin versus 12.5% (eight of 64) with physician's choice, resulting in a between-group difference of 43.8% (95% CI 29.1-58.4; p<0.0001). Grade 3-4 adverse events were reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients in the physician's choice group. Peripheral neuropathy was seen in 44 (67%) of 66 patients in the brentuximab vedotin group (n=21 grade 2, n=6 grade 3) and four (6%) of 62 patients in the physician's choice group. One of the four on-treatment deaths was deemed by the investigator to be treatment-related in the brentuximab vedotin group; no on-treatment deaths were reported in the physician's choice group. Interpretation Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotrexate or bexarotene.
  • article 310 Citação(ões) na Scopus
    Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
    (2015) SCARISBRICK, Julia J.; PRINCE, H. Miles; VERMEER, Maarten H.; QUAGLINO, Pietro; HORWITZ, Steven; PORCU, Pierluigi; STADLER, Rudolf; WOOD, Gary S.; BEYLOT-BARRY, Marie; PHAM-LEDARD, Anne; FOSS, Francine; GIRARDI, Michael; BAGOT, Martine; MICHEL, Laurence; BATTISTELLA, Maxime; GUITART, Joan; KUZEL, Timothy M.; MARTINEZ-ESCALA, Maria Estela; ESTRACH, Teresa; PAPADAVID, Evangelia; ANTONIOU, Christina; RIGOPOULOS, Dimitis; NIKOLAOU, Vassilki; SUGAYA, Makoto; MIYAGAKI, Tomomitsu; GNIADECKI, Robert; SANCHES, Jose Antonio; CURY-MARTINS, Jade; MIYASHIRO, Denis; SERVITJE, Octavio; MUNIESA, Cristina; BERTI, Emilio; ONIDA, Francesco; CORTI, Laura; HODAK, Emilia; AMITAY-LAISH, Iris; ORTIZ-ROMERO, Pablo L.; RODRIGUEZ-PERALTO, Jose L.; KNOBLER, Robert; PORKERT, Stefanie; BAUER, Wolfgang; PIMPINELLI, Nicola; GRANDI, Vieri; COWAN, Richard; ROOK, Alain; KIM, Ellen; PILERI, Alessandro; PATRIZI, Annalisa; PUJOL, Ramon M.; WONG, Henry; TYLER, Kelly; STRANZENBACH, Rene; QUERFELD, Christiane; FAVA, Paolo; MAULE, Milena; WILLEMZE, Rein; EVISON, Felicity; MORRIS, Stephen; TWIGGER, Robert; TALPUR, Rakhshandra; KIM, Jinah; OGNIBENE, Grant; LI, Shufeng; TAVALLAEE, Mahkam; HOPPE, Richard T.; DUVIC, Madeleine; WHITTAKER, Sean J.; KIM, Youn H.
    Purpose Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and Methods Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients. (C) 2015 by American Society of Clinical Oncology
  • article 93 Citação(ões) na Scopus
    Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
    (2017) QUAGLINO, P.; MAULE, M.; PRINCE, H. M.; PORCU, P.; HORWITZ, S.; DUVIC, M.; TALPUR, R.; VERMEER, M.; BAGOT, M.; GUITART, J.; PAPADAVID, E.; SANCHES, J. A.; HODAK, E.; SUGAYA, M.; BERTI, E.; ORTIZ-ROMERO, P.; PIMPINELLI, N.; SERVITJE, O.; PILERI, A.; ZINZANI, P. L.; ESTRACH, T.; KNOBLER, R.; STADLER, R.; FIERRO, M. T.; VIOLETTI, S. Alberti; AMITAY-LAISH, I.; ANTONIOU, C.; ASTRUA, C.; CHAGANTI, S.; CHILD, F.; COMBALIA, A.; FABBRO, S.; FAVA, P.; GRANDI, V.; JONAK, C.; MARTINEZ-ESCALA, E.; KHETERPAL, M.; KIM, E. J.; MCCORMACK, C.; MIYAGAKI, T.; MIYASHIRO, D.; MORRIS, S.; MUNIESA, C.; NIKOLAOU, V.; OGNIBENE, G.; ONIDA, F.; OSELLA-ABATE, S.; PORKERT, S.; POSTIGO-LLORENTE, C.; RAM-WOLFF, C.; RIBERO, S.; ROGERS, K.; SANLORENZO, M.; STRANZENBACH, R.; SPACCARELLI, N.; STEVENS, A.; ZUGNA, D.; ROOK, A. H.; GESKIN, L. J.; WILLEMZE, R.; WHITTAKER, S.; HOPPE, R.; SCARISBRICK, J.; KIM, Y.
    Background: Advanced-stage mycosis fungoides (MF)/Sezary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment options for the different stages but without recommending treatments in any particular order due to lack of comparative trials. The aims of this second CLIC study were to retrospectively analyze the pattern of care worldwide for advanced-stage MF/SS patients, the distribution of treatments according to geographical areas (USA versus non-USA), and whether the heterogeneity of approaches has potential impact on survival. Patients and methods: This study included 853 patients from 21 specialist centers (14 European, 4 USA, 1 each Australian, Brazilian, and Japanese). Results: Heterogeneity of treatment approaches was found, with up to 24 different modalities or combinations used as first-line and 36% of patients receiving four or more treatments. Stage IIB disease was most frequently treated by total-skinelectron-beam radiotherapy, bexarotene and gemcitabine; erythrodermic and SS patients by extracorporeal photochemotherapy, and stage IVA2 by polychemotherapy. Significant differences were found between USA and non-USA centers, with bexarotene, photopheresis and histone deacetylase inhibitors most frequently prescribed for first-line treatment in USA while phototherapy, interferon, chlorambucil and gemcitabine in non-USA centers. These differences did not significantly impact on survival. However, when considering death and therapy change as competing risk events and the impact of first treatment line on both events, both monochemotherapy (SHR = 2.07) and polychemotherapy (SHR = 1.69) showed elevated relative risks. Conclusion: This large multicenter retrospective study shows that there exist a large treatment heterogeneity in advanced MF/SS and differences between USA and non-USA centers but these were not related to survival, while our data reveal that chemotherapy as first treatment is associated with a higher risk of death and/or change of therapy and thus other therapeutic options should be preferable as first treatment approach. Key words: mycosis fungoides, CTCL, prognosis, treatment,
  • article 50 Citação(ões) na Scopus
    Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
    (2021) HORWITZ, Steven M.; SCARISBRICK, Julia J.; DUMMER, Reinhard; WHITTAKER, Sean; DUVIC, Madeleine; KIM, Youn H.; QUAGLINO, Pietro; ZINZANI, Pier Luigi; BECHTER, Oliver; ERADAT, Herbert; PINTER-BROWN, Lauren; AKILOV, Oleg E.; GESKIN, Larisa; SANCHES, Jose A.; ORTIZ-ROMERO, Pablo L.; WEICHENTHAL, Michael; FISHER, David C.; WALEWSKI, Jan; TROTMAN, Judith; TAYLOR, Kerry; DALLE, Stephane; STADLER, Rudolf; LISANO, Julie; BUNN, Veronica; LITTLE, Meredith; PRINCE, H. Miles
    The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting >_4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL). Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptom burden with no negative effects on quality of life. We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30expressing MF/C-ALCL were randomly assigned to brentuximab vedotin (n = 64) or physician's choice (n = 64). Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs physician's choice: ORR4; 54.7% vs 12.5% (P < .001); complete response, 17.2% vs 1.6% (P = .002). Median PFS with brentuximab vedotin vs physician's choice was 16.7 months vs 3.5 months (P < .001). Median time to the next treatment was significantly longer with brentuximab vedotin than with physician's choice (14.2 vs 5.6 months; hazard ratio, 0.27; 95% confidence interval, 0.17-0.42; P < .001). Of 44 patients in the brentuximab vedotin arm who experienced any-grade peripheral neuropathy, (grade 3, n = 6; grade 4, n = 0), 86% (38 of 44) had complete resolution (26 of 44) or improvement to grades and 2 (12 of 44). Peripheral neuropathy was ongoing in 18 patients (all grades 1-2). These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL. This trial was registered at https://www.clinicaltrials.gov as #NCT01578499.
  • article 29 Citação(ões) na Scopus
    Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
    (2021) KIM, Youn H.; PRINCE, H. Miles; WHITTAKER, Sean; HORWITZ, Steven M.; DUVIC, Madeleine; BECHTER, Oliver; SANCHES, Jose A.; STADLER, Rudolf; SCARISBRICK, Julia; QUAGLINO, Pietro; ZINZANI, Pier Luigi; WOLTER, Pascal; ERADAT, Herbert; PINTER-BROWN, Lauren C.; ORTIZ-ROMERO, Pablo L.; AKILOV, Oleg E.; TROTMAN, Judith; TAYLOR, Kerry; WEICHENTHAL, Michael; WALEWSKI, Jan; FISHER, David; MCNEELEY, Marise; GRU, Alejandro A.; BROWN, Lisa; PALANCA-WESSELS, M. Corinna; LISANO, Julie; ONSUM, Matthew; BUNN, Veronica; LITTLE, Meredith; TREPICCHIO, William L.; DUMMER, Reinhard
    Introduction: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III AL-CANZA study. Methods: Baseline CD30 levels and large-cell transformation (LCT) status were centrally reviewed in patients with previously-treated CD30-positive MF using >= 2 skin biopsies obtained at screening; eligible patients required >= 1 biopsy with >= 10% CD30 expression. Patients were categorised as CD30(min) < 10% (>= 1 biopsy with <10% CD30 expression), or CD30(min) >= 10% (all biopsies with >10% CD30 expression) and baseline LCT present or absent. Efficacy analyses were the proportion of patients with objective response lasting >= 4 months (ORR4) and progression-free survival (PFS). Results: Clinical activity with brentuximab vedotin was observed across all CD30 expression levels in patients with >= 1 biopsy showing >= 10% CD30 expression. Superior ORR4 was observed with brentuximab vedotin versus physician's choice in patients: with CD30(min) < 10% (40.9% versus 9 .5%), with CD30(min) >= 10% (57.1% versus 10.3%), with LCT (64.7% versus 17.6%) and without LCT (38.7% versus 6.5% ). Brentuximab vedotin improved median PFS versus physician's choice in patients: with CD30(min) < 10% (16.7 versus 2.3 months), with CD30(min) >= 10% (15.5 versus 3.9 months), with LCT (15.5 versus 2.8 months) and without LCT (16.1 versus 3.5 months). Safety profiles were generally comparable across subgroups. Conclusion: These exploratory analyses demonstrated that brentuximab vedotin improved rates of ORR4 and PFS versus physician's choice in patients with CD30-positive MF and >= 1 biopsy showing >= 10% CD30 expression, regardless of LCT status. (C) 2021 The Authors.
  • conferenceObject
    Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: an international virtual study
    (2019) HODAK, Emmilia; ZIC, John; BAGOT, Martine; GRU, Alejandro A.; BATTISTELLA, Maxime; MITTELDORF, Christina; COZZIO, Antonio; GUENOVA-HOTZENECKER, Emmanuella; GUITART, Joan; GESKIN, Larisa; KNOBLER, Robert; ORTIZ, Pablo; PAPADAVID, Lia; QUERFELD, Christiane; QUAGLINO, Pietro; ROOKE, Bethanie; STADLER, Rudolf; SANCHES, Jose A.; DUVIC, Madeleine; JUNKINS-HOPKINS, Jacqueline; PULITZER, M. Melissa; KEMPF, Werner; HAUN, Paul; TORRES-CABALA, Carlos; ROBSON, Alistair; BELTRAMINELLI, Helmut; SUBTIL, Antonio; KIM, Youn; SCARISBRICK, Julia